Friday, 16 October 2026European Markets

NOVABASE,SGPS Stock Bearish Momentum With A 15% Drop In The Last 5 Sessions

Loading stream...

(VIANEWS) - Shares of NOVABASE,SGPS (PSI: NBA.LS) dropped by a staggering 15.14% in 5 sessions from €5.19 to €4.40 at 17:24 EST on Thursday, following the last session's downward trend. PSI is jumping 0.82% to €6,029.31, after four consecutive sessions in a row of gains.

NOVABASE,SGPS's last close was €4.50, 13.13% under its 52-week high of €5.18.

About NOVABASE,SGPS

Novabase S.G.P.S., S.A., through its subsidiaries, provides IT consulting and services in Portugal, Europe, Africa, the Middle East, and internationally. It operates through two segments, Next-Gen and Value Portfolio. The Next-Gen segment develops IT consulting and services to banks, insurance, capital markets, and telecommunication sectors. This segment operates under the Celfocus brand name. The Value Portfolio segment operates and develops IT consulting, staffing, and services under the Neotalent brand. This segment involves in venture capital activities. Novabase S.G.P.S., S.A. was incorporated in 1989 and is headquartered in Lisbon, Portugal.

Earnings Per Share

As for profitability, NOVABASE,SGPS has a trailing twelve months EPS of €0.23.

PE Ratio

NOVABASE,SGPS has a trailing twelve months price to earnings ratio of 19.13. Meaning, the purchaser of the share is investing €19.13 for every euro of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.08%.

Dividend Yield

According to Morningstar, Inc., the next dividend payment is on Jun 21, 2023, the estimated forward annual dividend rate is 0.1 and the estimated forward annual dividend yield is 2.29%.

Moving Average

NOVABASE,SGPS's worth is under its 50-day moving average of €4.76 and under its 200-day moving average of €4.45.

More news about NOVABASE,SGPS (NBA.LS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com